Table 2.

Associations between baseline patient characteristics and survival after definitive RT^a

Variable	HRb (95% CI)	P value
Age at start of RT (10-y increase)	1.26 (1.08-1.47)	.003
Male	1.63 (1.11-2.40)	.012
Primary cancer site		<.001
Head and neck	1.00 (reference)	NA
Breast	0.06 (0.01-0.24)	<.001
GI tract	0.94 (0.56-1.59)	.83
Genitourinary tract	0.04 (0.01-0.32)	.002
Lung	1.47 (0.85-2.56)	.17
Brain or CNS	1.23 (0.63-2.43)	.55
Soft tissue or bone	0.44 (0.15-1.23)	.12
Gynecologic site	0.71 (0.30-1.69)	.44
Skin	1.51 (0.67-3.41)	.32
Lymph node	0.47 (0.11-1.98)	.31
Stage		<.001
0 or 1	1.00 (reference)	NA
2	3.92 (1.69-9.06)	.001
3	5.73 (2.53-12.98)	<.001
4	4.37 (1.86-10.29)	<.001
Dose (1000-cGy increase)	1.01 (0.86-1.18)	.91
Metastatic at start of RT	1.19 (0.64-2.22)	.58
Chemotherapy at or before start of RT	2.38 (1.56-3.62)	<.001
Surgery at or before start of RT	0.57 (0.39-0.84)	.004

CI, confidence interval; CNS, central nervous system; GI, gastrointestinal; HR, hazard ratio; NA, not applicable; RT, radiation therapy.

^aHRs, 95% CIs, and P values were determined from unadjusted Cox proportional hazards regression models.

^bHRs correspond to the increase in parentheses for continuous variables and to the presence of the given characteristic for categorical variables.